Robert J. Coury
Net Worth

Last updated:

What is Robert J. Coury net worth?

The estimated net worth of Mr. Robert J. Coury is at least $74,204,750 as of 4 Mar 2023. He owns shares worth $2,677,500 as insider, has earned $5,087,250 from insider trading and has received compensation worth at least $66,440,000 in Viatris Inc..

What is the salary of Robert J. Coury?

Mr. Robert J. Coury salary is $16,610,000 per year as Executive Chairman in Viatris Inc..

How old is Robert J. Coury?

Mr. Robert J. Coury is 64 years old, born in 1961.

What stocks does Robert J. Coury currently own?

As insider, Mr. Robert J. Coury owns shares in one company:

Company Title Shares Price per share Total value
Viatris Inc. (VTRS) Executive Chairman 250,000 $10.71 $2,677,500

What does Viatris Inc. do?

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

VTRS logo
VTRS
Viatris Inc.
$10.71

Robert J. Coury insider trading

Viatris Inc.

Mr. Robert J. Coury has made 2 insider trades between 2021-2023, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 250,000 units of VTRS stock on 24 Jun 2021. As of 4 Mar 2023 he still owns at least 250,000 units of VTRS stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 4,441 N/A N/A
Option
Dividend Equivalent Units 4,440 N/A N/A
Option
Restricted Stock Units 123,529 N/A N/A
Option
Common Stock 123,529 N/A N/A
Option
Restricted Stock Units 100,770 N/A N/A
Option
Common Stock 100,770 N/A N/A
Option
Dividend Equivalent Units 7,968 N/A N/A
Option
Common Stock 7,969 N/A N/A
Sale
Common Stock 250,000 $10.07 $2,518,250
Sale
Common Stock 250,000 $10.28 $2,569,000
Option
Restricted Stock Units 100,770 N/A N/A
Option
Dividend Equivalent Units 2,408 N/A N/A
Option
Common Stock 100,770 N/A N/A
Option
Common Stock 2,409 N/A N/A
Option
Common Stock 250,000 N/A N/A
Option
Restricted Stock Units 250,000 N/A N/A

Viatris key executives

Viatris Inc. executives and other stock owners filed with the SEC: